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ABSTRACT
Establishment of an experimental system to study 
p53 effects in Saccharomyces cerevisiae 
Tuba Dinner
M. S. in Molecular Biology and Genetics 
Supervisor; Prof. Dr. Mehmet Öztürk 
August 1997, 82 pages
The aim of this vv^ ork was to establish an experimental model to study human 
wild type and mutant p53 protein effects in yeast Saccharomyces cerevisiae cells.
Wild type p53 was previously shown to be a DNA damage response gene that 
controls the genome stability in mammalian cells. We are interested in using yeast cells 
to study human p53-mediated cellular events after DNA damage. In this study we 
established an experimental model as an initial step. For construction o f this system 
pAK31 plasmid expressing a human mutant p53-248W as well as control plasmid pL3 
were used to obtain two different yeast cell populations, one expressing the mutant 
p53 248W protein and the other without p53 expression. Wild type p53 expression 
vector was avoided because o f its known growth inhibitory effects in yeast cells.
In this experimental system initially p53 expression at pAK31 transformed 
yeast cells was shown. Then, the effect o f mutant p53-248W expression to growth 
rate o f yeast cells was analysed and no growth rate difference was detected between 
the cells expressing and non-expressing mutant p53-248W protein. To test the 
participation o f mutant p53-248W protein in DNA damage response in yeast cells, 
cells were exposed to DNA damaging agents; UVC and cisplatin that were reported 
to induce wild type p53 protein in mammalian cells. Codon 248 is a common site of 
‘hot spot’mutation and the arginine residue that corresponds to codon 248 encoded 
by the wild type p53 sequence is in the DNA interacting face o f the p53 protein. 
Mutant p53-248 (arg->trp) is defective in specific DNA binding and it has lost the 
ability to act as a transcription factor. Although there are not many reports about 
mutant p53-248W response to DNA damaging agents, it was shown that mutant p53- 
248W exhibit decreased repair o f active genes upon UV radiation. In this study cell 
survival was analysed in mutant p53-248W protein expressing yeast cells in parallel to 
mutant p53 protein levels following to DNA damage and no effect o f mutant p53 
248W expression on cell survival upon DNA damage was detected. Also no 
difference was detected in mutant p53 protein levels following DNA damage.
Ill
ÖZET
p53 proteinin Saccharomyces cerevisiae mayasındaki etkilerini 
incelemek için deney sisteminin oluşturulması
Tuba Dinçer
Yüksek Lisans Tezi,Moleküler Biyoloji ve Genetik 
Bölümü Tez yöneticisi: Prof. Dr. Mehmet Öztürk 
Ağustos 1997, 82 Sayfa
Bu çalışmanın amacı, Saccharomyces cerevisiae maya hücrelerinde insan p53 
proteininin ve mutant formunun etkilerini görmek için deneysel bir modelin 
oluşturulmasıdır.
p53 proteininin DNA hasarına karşı tepki gösteren ve bu şekilde genom 
dengesini kontrol eden bir protein olduğu memeli hücrelerinde daha önce 
gösterilmişti. Biz DNA hasanna karşı insan p53 proteininin maya hücresinde 
gösterdiği etkilerle ilgilendik ve bunun için de ilk olarak mayada deneysel bir sistem 
kurduk. Bu deneysel sistemin oluşturulmasında, mutant p53-248W proteinini ekspres 
eden pAK31 plasmidi ve kontrol olarakta bu proteini ekspres etmeyen pL3 plasmidi 
kullanıldı. Bu şekilde mutant p53 ekspres eden ve etmeyen iki farklı maya hücre 
populasyonu oluşturuldu. p53 proteininin hücre çoğalmasım engellediğini gösteren 
raporlardan dolayı çalışmalarda p53 proteini kullanılmadı. Bu sistemde ilk olarak 
pAK31 vektörü ile transforme edilen maya hücrelerinde, p53 proteinininin 
ekspresyonu gösterildi. Daha sonra mutant p53-248W proteininin, maya hücrelerinin 
büyüme hızına etkisi analiz edildi ve mutant p53 ekspres eden ve etmeyen maya 
hücrelerinin büyüme hızında hiçbir fark görülmedi. Mutant p53-248W proteininin 
maya hücrelerinde, DNA hasanna karşı bir tepki gösterip göstermediğini kontrol 
etmek için maya hücreleri DNA hasanna yol açan, UVC-ışınlanna ve cisplatine maruz 
bırakıldı. Memeli hücrelerinde p53 proteininin DNA zaranna tepkisi daha önceden 
UVC-ışınları ve cisplatinle gösterilmişti. p53 geninin aıjinin amino asidine denk gelen 
248. kodonu en sık rastlanan mutasyon noktası olmasının yamsıra p53 proteininin 
DNA ile etkileşen kısmıdır. Mutant p53-248' in (arg->trp) DNA ile etkileşimindeki 
özgüllüğünden yoksun kalması dolayısıyla transkripsiyon faktörü olarak işlev görme 
özelliğini kaybeder. Mutant p53-248W proteininin DNA hasanna gösterdiği tepki 
hakkında çok fazla rapor bulunmamakla beraber, bir rapor da UVC-ışım karşısında 
mutant p53-248W proteininin aktif genlerin tamirini azalttığı gösterilmiştir. Bu 
çalışmada mutant p53-248 proteini ekspress eden maya hücrelerinin, DNA hasarı 
sonucunda hücrelerin canlı kalmasına olan etkisine paralel olarak, bu hücrelerde 
mutant p53 protein seviyeleri de incelenmiştir. DNA haşan karşısında mutant p53- 
248W proteininin canlı kalan maya hücresi sayısına etkisi belirlenmediği gibi p53 
protein seviyesinde de bir farklılık görülmemiştir.
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1. INTRODUCTION
The p53 is a 53 kDa nuclear phosphoprotein that suppresses abnormal cell 
proliferation and plays an important role for protection against cancer. p53 has been 
named as “guardian of the genome” by researchers to indicate its dictatory role in control 
o f the genomic integrity. Recent studies indicate that the p53 protein is involved in gene 
transcription, DNA synthesis and repair, senescence, genomic plasticity, and in 
programmed cell death.
The p53 gene and protein product have become the center o f study ever since it 
become clear that more than 50 % of human cancers contain mutations in this gene.
These mutations were detected in more than 50 different cell lines and tissue types 
(Hollstein et a l, 1994). The nature of these mutations in cancer cells is most commonly a 
missense mutation in one allele, producing a faulty protein that is than observed at high 
concentrations in these cells. Deletions or chain termination mutations in the p53 gene 
were obtained rarely. On the other hand, p53 “knockout” mice (no p53 expression or p53 
-/-) were shown to be prone to different tumor development (Donehower et al., 1992).
p53 is a component o f biochemical pathways central to human carcinogenesis 
(Harris, 1993). p53 protein alterations due to mostly missense mutations and rarely loss 
o f p53 protein by nonsense or ffameshift mutations provide a selective advantage for 
clonal expansion o f preneoplastic and neoplastic cells. There have been some suggestions 
that the missense mutant producing a faulty p53 protein could contribute to a “gain o f
function” phenotype in addition to the abrogation o f p53 function (Dittmer et al., 1993). 
p53 protein levels are mostly regulated by posttranslational mechanisms (Finlay et al., 
1988). Degradation o f p53 may involve ubiquitin-dependent proteolysis; most mutations 
o f p53 disturb the degradation pathway, resulting in particularly high levels o f the mutant 
protein (Scheffiier et al., 1990).
The mutational spectra at the p53 locus in different tissue types indicates a strong 
role for diverse environmental mutagens with a set o f tissue preferences (Bressac et al., 
1991; Hsu et al., 1991; Brash et al., 1991). In addition there is strong selection for subset 
mutations localised predominantly in the DNA binding domain of p53 (Lin et al., 1995). 
Thus both selection and a strong set o f environmental mutagens combine to produce 
mutations in the p53 gene in human cancers.
2.GENERAL mFORMATION
2.1. p53 and cancer
Tumour suppressor genes maintain tissue homeostasis by controlling cellular 
proliferation, terminal differentiation and apoptosis (Weinberg e ta l, 1991). The p53 
tumour suppressor gene has become a hot topic o f cancer research because it is 
commonly mutated in human cancers and spectrum o f p53 mutations in these cancers
provide clues about the etiology and molecular pathogenesis o f cancer (Harris et ah,
1993 ; Hollstein et al., 1991). Statistic value indicates that, o f the ~6.5 million cancer 
cases worldwide each year, 2.4 million tumours are estimated to contain a p53 mutation. 
About 50 % o f human cancers contain p53 mutations, including the cancers o f the breast, 
cervix, colon, liver, prostate, bladder, and skin and these cancers are more aggressive, 
more prone to metastasise, and more fatal (Harris et al., 1996).
2.2, Historic landmarks of p53
The nuclear phosphoprotein p53 was originally discovered in extracts o f 
transformed cells, reacting with antiserum from animals with tumours induced by Simian 
Virus 40 (SV40) (Linzer and Levine, 1979; Lane and Crawford, 1979). The protein was 
found to form an oligomeric complex in SV40 transformed cells with the SV40 oncogene 
product; the large T antigen. It was known that large T antigen is required for 
maintenance o f transformed phenotype. p53 protein was also coprecipitated with E lB - 
55 kDa protein that cause a transformed phenotype (Samow et al., 1982). At this time 
p53 was classified as a tumour antigen. The levels o f p53 in cells containing those 
complexes were approximately 100 fold higher than in the non transformed cells and the 
half life o f p53 is correspondingly extended from 20 min to 24 hr (Reich et al., 1983 ; 
Oren et al., 1981). The results o f further studies have supported the hypothesis that 
increased levels o f p53 effect phenotype o f the normal cells; overexpression o f p53 
resulted in the immortalization o f rodent cells ( Jenkins et al., 1984 and Rovinski and 
Benchimol,1988) and in conjunction with an activated ras oncogene in rodent cells, p53
3
induced tumourogenic phenotype formation (Eliyahu et al., 1984, Parada e ta /., 1984). 
However all o f these studies were performed with a expressing a mutant forms of p53 
(Hinds et ah, 1989, Finlay et al., 1988, Eliyahu et al., 1988). When wild type p53 was 
introduced in to the cells, it suppressed the transformation o f cells in culture by other 
oncogenes like ras (Finlay et al., 1989). DNA screened from colon cancer patients 
revealed that p53 mutations occur with usually high frequency in tumour tissue (Baker et 
al., 1989). It is frequently altered by somatic mutations in a wide variety o f human 
neoplasms (Hollstein et al., 1991). Beside spontaneous human cancers, germline p53 
mutations are found at Li-Fraumeni syndrome in which affected family members develop 
cancers at a young age (Malkin et al., 1990). High incidence o f tumours in p53 knockout 
mice is detected by six mounts o f age (Donehower et al., 1992). All these results 
confirmed that p53 is a tumour suppressor gene that requires loss o f function mutations 
for tumour formation but some mutant forms o f p53 exert a transdominant negative effect 
on normal p53 that result in gain o f  function for carcinogenesis (Milner et al., 1991, 
Srivastava e /a /., 1993).
2.3. Structure of p53
2.3.1. p53 domains: structure-function relationship 
p53 is a phosphoprotein o f  about 393 amino acids which can be divided 
into five domains. p53 has been shown to possess a transcriptional activation function and 
transcriptional activation domain has been mapped to the 1-42 amino acid residues at N- 
terminus that interacts with the basal transcription machinery (L ine/a/., 1994).The
sequence specific DNA binding domain o f p53 localised between amino acid residues 
102 and 292, the central part o f the protein referred as core domain. The crystal structure 
o f a complex containing the core domain and DNA has been determined at 2.2 A° 
resolution (Cho et ah, 1994). More than 90 % p53 o f mutations occur in this core 
domain and 40 % o f the missense mutations are localised to residues R175, G245, R248 
R249, R273, and R282 which play a role in the structural integrity o f this domain (Cho et 
al., 1994). p53 is a nuclear protein , a nuclear localisation sequence was found between 
amino acid residues 3 16-325.(Shaulsky et a l, 1990). The native p53 protein is a tetramer 
in solution. C terminal domain between amino acid residues 323 and 355 in human p53 
was mapped as oligomerization domain. Crystal structure o f the tetramerization domain 
has been determined at 1.7 A° resolution (Jeffrey et al., 1995). The tetrameric form of 
p53 protein that is a dimer o f a dimer, binds to four repeats o f consensus DNA sequence 
5’- PuPuPuC(A/T)-3’and this sequence is repeated in two pairs, each arranged in inverted 
repeats such a s ^  <— > where is the sequence written above. This consensus
sequence was identified in the promoter and/or an intronic regions o f the genes that are 
transactivated by p53 (El- Deiry et al., 1992). The highly basic extreme C terminus which 
is connected to oligomerization domain with a flexible linker between the residues 368- 
387 can bind DNA sequence non-specifically and regulate non DNA binding-latent form 
o f p53. This region negatively regulates p53 sequence specific DNA binding and deletion, 
phosphorylation by protein kinase C or casein kinase II, binding of antibody Pab421 to 
this sequence all activate latent state o f p53 and provides its sequence specific DNA 
binding (Hupp and Lane et al., 1994). The fifth domain defined approximately by amino 
acids 61-94 o f human p53 contains five repeats o f amino acid sequences PXXP (P
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designate proline and X designate any amino acid). The fundamental importance o f 
PXXP sequence, is supported by the fact that these motifs have been found in all proteins 
known to bind directly to SH3 domain which have important roles in signal transduction. 
A p53 cDNA deletion mutant (Apro AE) which lacks the entire fifth domain has been 
shown to be completely dispensable for transcriptional activation. On the other hand a 
deletion o f this p53 proline rich domain impairs p53 ability to suppress tumour cell 
growth. In addition to transcriptional activation domain, prolin rich domain may play a 
critical role in the transmission o f downstream signal (Walker and Levine, 1996).
Domains of p53 protein are shmematically presented in Fig. 1.
2.3.2. Structural aspects o f the p53 protein in relation to gene evolution 
According to sequence analysis o f various p53 proteins five highly conserved 
blocks were identified (Soussi et al., 1990). Four o f these five blocks (II to V) are found 
in the central domain and block I is located in the N-terminal.
Starting with vertebrates, a large number o f p53 genes from different species have 
been characterised. Interestingly p53 was also identified in invertebrates such as squid 
(Ishioka et al., 1995). Despite existence o f p53 in diverse organisms, up to now no 
protein homologous have been identified in lower eukaiyotes like Drosophila and yeast.
2.3.3. Highly conserved regions that coincide with the mutation clusters o f p53 
found in human cancers.
Mutations in p53 have been shown to occur at nearly every position, with a 
preferential occurrence in III, IV, V conserved blocks, like the mutations R175 found in 
III*'’ block; R248, G 245 and R249 found in IV conserved block; R273 and R282 found 
in V"* conserved domain (Fig 1). Those mutations are p53 somatic mutations that are 
frequently seen in human tumours and cell lines (Hollstein et al., 1994).
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Fig.1. Schematic presentation of human p53. Several hot spots for mutations R175, 
G245, R248, R249, R273, R282 are also Indicated
2.4. The cellular functions of p53
The high frequency of p53 alterations in human cancers suggests that p53 play a 
critical role in the control o f the growth o f normal cells. A number o f biological and 
biochemical functions have been ascribed to wild type p53. Importantly mutant p53 
proteins derived from human tumours are defective in some o f these functions, suggesting 
that such functions like cell cycle arrest, apoptosis, transcriptional activation and 
repression, DNA repair and replication are relevant for p53 mediated growth control and 
tumour suppression
2.4.1. Mechanism leading to cell cycle arrest
All cells have mechanisms for coping with DNA damage. Most eukaryotic cells 
respond to DNA damage with transient delays in both G1 and G2 phases presumably to 
allow for repair prior to DNA replication or division o f the cell. It was shown that tumour 
suppressor p53 required for the G1 check point function in mammalian cells (Kastan et 
a l, 1992; Kuerbitz et a l, 1992). Fibroblasts from p53 nullizygous mice lack the G1 
checkpoint function (Kastan et al., 1992). Furthermore, normal human fibroblasts induce 
p53 and cause its accumulation in response to ionizing radiation (IR) whereas fibroblasts 
from the Ataxia talengiectesia (AT) patients are defective in this response (Kastan et al., 
1992). This response of p53 to DNA damage was also shown in many different cell types; 
cell lines having wt p53, exhibit G1 arrest following radiation, p53-null cells such as 
Saos-2 cells continue to progress through S phase (Kuerbitz et al., 1992). Cells with 
mutant p53 enter S phase and amplify segments o f DNA, Li-Fraumeni syndrome cells
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containing wt p53 arrested in G1 and did not go gene amplification, the converse occur in 
cells lacking w t p53 (Yin et a l, 1995).
The amount o f p53 in mouse cells increases 5-10 fold a few hours after UV 
irradiation or treatment with the DNA damaging drug 4NQO (Maltzman and Czyzyk. 
1984).
In normal conditions p53 is a labile protein. By pulse-chase experiments half life 
o f p53 protein in untreated cells found to be 20 min. Agents which damage DNA induce 
p53 to become very stable (Mosner et a l, 1995). The same group suggest that p53 is 
negatively auto-regulated by specifically inhibiting translation o f its own mRNA in vitro. 
According to studies in hepatocytes; nuclei of untreated cells were always negative for 
immune detectable p53. In contrast, nuclei o f UV damaged DNA stained positively for 
p53 (Sun et al., 1995). Additionally a novel p53 promoter that contains 80 bp was 
identified which is induced by genotoxic stress such as anti cancer drugs and UV (Sun et 
al., 1995).
The ability o f p53 to serve as a transcription activator suggests a mechanism for 
the induction o f  the damage responsive transcripts that might influence the cell cycle 
progression. A strong candidate is (Nauba et a l, 1995; El-Deiry et a l, 1993;
Harper et a l, 1993), which is activated by p53 and likely to play an important role in the 
p53-induced DNA damage because it encodes a potent cyclin dependent kinase inhibitor.
By this way p21 CIPl /WAFlprevents phosphorylation o f the G1 cyclin/ CDK substrate pRB,
thereby preventing the transition from G1 phase to S phase (Slebos e ta l, 1994).
DNA damage is the triggering factor for the induction o f p53 activation. Types o f 
DNA damage that activate p53 were also studied. The experiments indicate that p53
dependent arrest mechanism can be activated by very few double strand breaks, and only 
one may be sufficient. In addition to double strand break, nuclear injection o f linearized 
plasmid DNA, circular DNA with a large gap or single stranded phagemid DNA is 
sufficient to induce a p53 dependent cell cycle arrest (Huang et al., 1996).
Beside G1 arrest, p53 has also been implicated in G2/M phase checkpoint. When 
mitotic spindle inhibitors are added to the cells with wild type p53, the cells are blocked 
in G2. In the absence o f wild type p53, the cells re-initiate DNA synthesis (Cross et a l, 
1995). If  the radiation applied before G1 checkpoint, the fibrosarcoma cells undergo G1 
arrest without subsequent G2 arrest and if the cells are irradiated after G1 checkpoint, 
cells undergo G2 arrest without subsequent G1 arrest. Furthermore in those cell lines 
which do not go radiation-induced apoptosis, the wild type p53 exhibit radioresistance in 
terms o f clonogenic survival (Pellegata et a l, 1996).
2.4.2. Induction o f apoptosis
p53 initiate apoptosis if the damage to cell is severe. This protects the organism 
from the growth o f damaged cells. p53 plays a role in triggering apoptosis under different 
physiological conditions. Normal thymocytes will undergo apoptosis in response to DNA 
damage whereas thymocytes from p53 (-/-) mice don’t undergo apoptosis in response to 
same stimulus (Lowe et al., 1993). A number o f factors affect the decision o f a cell to 
enter p53-mediated cell cycle arrest or apoptotic pathway; under conditions in which the 
DNA is damaged, if survival factors are limiting or an activating oncogene is forcing the 
cell in to a replicative cycle, p53 induced apoptosis prevails. Two o f the genes that are 
regulated by p53 could influence the decision to commit to an apoptotic pathway; Bax
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and IGF-BP3 (Miyashita and Reed, 1995; Bucbinder et ah, 1995). Bax regulate apoptosis 
by binding to BCL-2 that is a blocker o f  apoptosis and IGF induce apoptosis by lowering 
the mitogenic response o f cell. Sequence specific transcription capacity of p53 is very 
important for induction o f apoptosis like in the case o f induction of Bax and IGF-BP3, 
but beside this, it was shown that a truncated p53 protein lacking sequence specific 
transcription capacity is able to induce apoptosis in He-La cells. This result indicated the 
existence o f another p53-dependent apoptotic pathway o f which occur without sequence 
specific transcription function o f  p53 (Haupt et al., 1995).
2.4.3. Transcriptional activation and repression by p53 
p53 is a potential transcription factor (Fields and Jang et a l, 1990) and once 
activated, it repress the transcription o f one set o f genes, like c-fos, c-jun, IL-6, Rb and 
Bcl-2. It was reported that only promoters containing initiator elements and lacking p53 
binding sites are inhibited by p53 (Mack et al., 1993). It stimulates the expression of 
other genes that have p53 binding sites, some o f the target genes identified so far include; 
p21AVaf 1/CIPl which is a cyclin dependent kinase inhibitor that combine with cyclins 
and PCNA and cause G1 arrest o f cell cycle (El-Deiry et al., 1993; Harper et al., 1993) 
mdm-2 is a oncoprotein which is a cellular inhibitor o f the p53 in that it can bind to 
transactivation domain and form an autoregulatory loop with p53 activity (Oliner et al., 
1992), Gadd-45 is induced when cells are subjected to DNA damage leading to arrest in 
G1 (Kastan et al., 1992). It interacts with PCNA and inhibits DNA replication; cyclin G 
is a novel cyclin that is strongly activated in a p53-dependent manner in cells subject to 
DNA damage (Zauberman et al., 1995), bax is a member of bcl-2 family that promotes
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apoptosis (Miyashita and Reed, 1995), IGF BPS is induced in cells after DNA damage. It 
is anti-mitogenic factor (Bucbinder et al., 1995). Many effects o f p53, like growth arrest, 
apoptosis and inhibition o f carcinogenesis can be attributed to the biological functions of 
its downstream genes.
2.4.4. Involvement o f p53 in cellular DNA replication and repair 
In addition to the damage-induced p53 functions, evidence for a direct 
involvement o f p53 in cellular DNA replication and repair has accumulated. The products 
o f two different p53 target genes, and Gadd45 has been shown to interact with
PCNA, a factor that is involved in DNA replication, both GADD45 and p21 discard 
PCNA from DNA replication via binding to it (Waga et al., 1994; Smith et al., 1994). 
These results suggest the idea that p53 involve in DNA replication regulation by inducing 
GADD45 and p21.
There are also evidences for a direct involvement o f p53 in cellular DNA repair. 
Such an involvement can be deduced from several findings. In addition to sequence 
specific DNA binding, p53 protein binds non-specifically to double stranded (ds) and 
single stranded (sd) DNA (Kern et al., 1991). Furthermore it has been described to 
reanneal both RNA and DNA (Balkalkin et al., 1994). These functions might be 
important in the processes associated with DNA repair like recognition o f DNA damage 
in the form o f deletion insertion deletion mismatches (Lee et al., 1995) and prevention of 
unscheduled recombination (Bertrand et al., 1997). Another function o f p53 is its Mg^^ 
dependent 3 -5 exonuclease activity that could be mapped to the central core domain of 
p53 protein, mammalian cells contain a variety o f different exonucleases like PCNA
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dependent polymerase Ô and s involved in DNA replication, recombination and 
proofreading repair (Mummenbrauer et al., 1996).
In addition, physical interaction between the human RAD 51 (homologues o f 
bacterial Rec A) and wt p53 but not mt p53 was found in vivo. According to results; it 
was shown that this interaction inhibit RAD 51 which catalyses three strand exchange and 
ATPase activity. It was suggested that this physical interaction might play a major role in 
controlling the extent and timing o f homologous recombination which is so important for 
the genome stability (Sturzbecher e ta l, 1996). Further investigations about p53 effect on 
homologous recombination in mammalian cells expressing a mutant p53 protein showed 
that mt p53 increase the intrachrosomal homologous recombination (Bertrand et al., 
1997).
Also there are some clues about the p53 involvement in nucleotide excision repair 
(NER) an important and versatile DNA repair mechanism, which is the major pathway for 
repair of UV-type lesions and damage by a variety o f important carcinogens and 
mutagens. During the studies to determine the effects o f p53 on cellular sensitivity to UV 
irradiation and on NER in primary human skin fibroblasts from patients o f Li-Fraumeni 
Syndrome, it was found that p53 mutant cell lines were resistant to UV-induced 
cytoxicity and apoptosis but deficient in global repair (Ford et al., 1995). According to in 
vitro data, host cell reactivation experiments with a reporter plasmid that is damaged with 
UV, mutant p53 containing cell lines showed reduced repair o f UV induced DNA lesions 
(Smith et a l, 1995; Mckay et a l, 1997).
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The upstream events or signals flowing to p53 are mediated by several stressful 
situations. In addition to DNA damage, hypoxia is also able to stimulate p53 levels and 
activate p53 protein (Graeber et al., 1996). Another signal that activates p53 is generated 
when ribonucleoside triphosphate pools fall below the critical value (Linke et al., 1996). 
In the case o f p53 activation, activated p53 may induce either growth arrest or apoptosis 
via transcriptional control or non-transcriptional control to maintain genomic integrity of 
cell. Figure 2 shows the major pathways leading to p53 activation and p53 mediated 
cellular changes.
2.4.5. The events in the p53 activation and its response
[HYPOXIA I ^?ENOTOXIC DAMAGE | METABOLIC CHANGES
Cellular stress
pia
N/
Active p53
V
direct signaiiing
Upstream
Transcriptional 
Activation
p21
Figure 2. The p53 pathway 
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2.5.The p53 and yeast cells
Although the term tumour suppressor connotes a function attributable only to 
multicellular organism, the control of DNA damage and cell cycle progression is critical 
to all eukaryotes. Genes in which recessive mutations uncouple growth arrest signals 
from cell cycle progression can be considered as yeast paradigms o f tumour suppressor 
genes. For example, in S.cerevisiae; Rad9, Radl7, Rad24, Mec3, involve in recognition 
o f DNA damage and Pol2, Rfc5, Dpbl 1 involve in replication recognition o f  replication 
blocks; and the genes M ecl, Rad53 and Dunl that transduce the growth arrest signals 
(Elledgee/a/., 1996).
Although homologous of p53 protein has not been identified in yeast, there are 
several studies that demonstrate similarity between the effects o f wild type and mutant 
p53 expression in yeast and human cells. Experiments in S.cerevisiae and S. pombe with 
human p53 indicates that p53 can alter the growth o f lower eukaryotic cells. According 
to studies in S.cerevisiae, the difference among colony growth between the cells 
expressing wild type human p53, mutant p53; mutant (Ala-143), mutant (His-273); and 
no p53 was shown. Colony growth difference was detected among the cells expressing 
exogenous wild type p53, mutant p53, and no p53 (vector with or without insert). 
Colonies expressing wild type p53 were considerably smaller than the control colonies. 
Cells producing the Ala-143 mutant grew almost as well as the control cells, while cells 
expressing the His 273 mutant exhibited an intermediate colony site. Colonies containing 
vector alone (no p53) had a doubling time o f 4.4 hr. The doubling time o f cells containing
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the wild type p53 was increased to 11.6 h and the doubling time of the strains containing 
the his-273 mutant was 6.5 hr. Also phase o f the cell cycle of these arrested cells were 
determined by flow cytometry. Strains containing wild type p53 exhibited G1 and G2/M 
peaks. In those experiments, it was also observed that coexpression o f p53 with the 
human cell cycle-regulated kinase, but not the yeast homologue CDC28, severely 
inhibiting cell growth and S.cerevisiae expressing both p53 and CDC2H accumulated 
largely in G1 phase. P53 was phosphorylated in S.cerevisiae but differences in 
phosphorylation did not account for the apparent growth rate observed in various strains 
containing p53 and CDC2H2 (Nigro et al., 1992). The same effect o f p53 to the growth 
o f fusion yeast; S.pombe was also observed (Biscoff et al., 1992). Wild type and two 
mutant polypeptides His 273, His 175 were expressed to similar levels in S.pombe and 
after 24 hr expression, although wild type p53 caused S.pombe to stop dividing, two 
mutant forms continued to divide slowly compared to non p53 expressing cells. In 
mammalian cells, p53 is predominantly a nuclear protein (Shaulsky et al., 1990). The p53 
cellular localisation was also studied in S.pombe and it was shown that wild type protein 
was localised to the nucleus, the mutant polypeptides exhibited more extranuclear 
staining than wild type p53 did. p53 is highly phosphorylated in mammalian cells. It was 
shown that wild type p53, when expressed in S.pombe, was phosphorylated on serine 315 
and serine 392 by casein kinase II and cdc2 kinase. It was shown that phosphorylation at 
Ser-315 and Ser-392 doesn’t effect p53 growth inhibitory function in S.pombe. Also an 
S.pombe strain was constructed to identfy dominant mutant alleles o f p53. Several 
different mutant alleles o f human p53 were introduced to wild type p53 expressing 
S.pombe strain to release it from the growth inhibitory effects of wild type p53. The His-
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175 that has been shown dominant to the wild type p53 in mammalian cells, were also 
detected as dominant in this assay (Biscoff et al., 1992).
p53 is a transcription activator ( Fields and Jang et al., 1990). It was shown that 
mammalian wild type p53 expressed in S.cerevisiae was able to activate transcription of a 
reporter gene under the control o f a CYCl hybrid promoter containing the 33 base pair 
p53 binding sequence whereas three mutants commonly found in human tumours, 175H, 
248W, 273H were unable to activate transcription (Scharer et al., 1992). Based on this 
function continuity o f p53 in yeast, assays have been developed to detect p53 mutations. 
Dominant negative p53 mutations were selected by yeast transcriptional assay, using 
URA3 as a reporter gene under the ADHl promoter that contain p53 consensus DNA 
binding sequence. According to this assay dominant-negative p53 mutations that suppress 
wild type p53 transcription activity were screened according to their Ura' Foa^ phenotype 
( Brachmann et al., 1996). Also the effect o f p53 mutations in the carboxy terminal to the 
transcription activity o f p53 was investigated using yeast transcriptional activity (Ishioka 
et al., 1995). For detection o f p53 mutations in blood samples, in tumours and in cell 
lines, yeast transcription assay was developed (Flaman et al., 1995).
During the studies to understand the mechanism o f p53 transcription activity 
regulation in yeast S. cerevisiae, mutants were generated by EMS and UV mutagenesis 
that are defective for p53 transcription activity. To study sequence specific transcription 
activity (SST), S cerevisiae was transformed by two vector, one o f them was p53 
' expressing plasmid and the other contained a reporter gene under the control o f URA3 
promoter that had specific p53 DNA binding site. Following cDNA screening to find a 
gene that complements SST p53 activity in yeast, PAKl gene was identified. It was found
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that all these mutants were complemented by PAKI gene, which is a ser/thr kinase. 
Expression o f PAKI was associated with an increased specific activity o f p53 in DNA 
binding assay and corresponding increased in transactivation (Thiagalingam et a l, 1995).
In an attempt to identify the p53 like a protein in the yeast S.cerevisiae, a mutant 
yeast cell that require wild type p53 for its viability was isolated. The mutant, rft-1, is 
defective in cell cycle progression and arrests before mitosis in the deficiency o f p53. 
According to genetic and biochemical studies, it was shown that p53 complement the 
activity o f rft-1 by forming a protein-protein complex (Koerte et al., 1995).
Although there are homologues o f mammalian genes in yeast involved in DNA 
damage and checkpoints like the S.cerevisiae genes; M ECl, TELİ, POL2 which are the 
homologues o f human genes; ATR, ATM, Pole respectively, there is no homologue of 
another cell cycle control p53 gene (Elledge, 1996). But expression o f wild type p53 
affects yeast cell growth (Nigro et al., 1992). Additionally p53 conserve its sequence 
specific transcription activity in yeast (Shrarer et al., 1992) and a yeast gene that 
complement this activity was found (Thiagalingam et al., 1995). All these results 
encourage the further studies to investigate other p53 effects in yeast.
p53 response to DNA damage in yeast has not been studied yet. According to 
studies in mammalian cells upon DNA damage, p53 is activated, it is stabilised, 
accumulated in the nucleus and induce downstream genes to keep genomic stability.
In this study an experimental system was established to study p53 response in 
yeast S.cerevisiae upon DNA damage. Considering the difficulties to use wild type p53 
due to it’s growth inhibitory effect in S.cerevisiae (Nigro et al., 1992), mutant p53 was
preferred to establish this experimental system. As mutant, R248 (CCG-^TGG) which is
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one of the most common p53 mutation detected in human tumours (Cho et al., 1994) was 
preferred. One o f the DNA damaging agents used in this study was UVC (254 nm); the 
amount of p53 in mouse cells increases 5-10 fold a few hour after UV radiation 
(Maltzman and Czyzk, 1984). UV induced nuclear accumulation o f p53 was also 
detected in primary human fibroblasts (Yamaizumi and Sugano, 1994). Beside p53 
accumulation upon UV type DNA damage, it’s involvement in repair o f UV type DNA 
damage was also shown (Smith et al., 1995).
In studies about p53. It was shown that p53 response might differ according the 
status o f DNA damaging agents (Zhang et al., 1996, Vasey et al., 1996). To confirm the 
p53 effects upon DNA damage in yeast another DNA damaging agent was used. In this 
case as direct DNA damaging agent cis-diamminedichloroplatinium(II) (cisplatin) was 
preferred. Cisplatin is an important anticancer drug which destroys tumour cells by 
forming covalent adducts on DNA, blocking polymerases, and preventing replication, 
transcription and cell division (Bruhn et al., 1990). It was shown that treatment o f  mouse 
teratosarcoma cells with this chemotherapeutic agent led to an increase o f p53, 3 h after 
addition o f the drug (Küpper et al., 1994). In S. cerevisiae cisplatin was also used as a 
DNA damaging agent to identify specific protein that bind cisplatin-DNA adducts (McA’ 
Nulty andLippard, 1996).
In this study an experimental system was developed to study the effects o f  wild 
type and mutant p53 protein following DNA damage.
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3. Materials and Methods
3.1. Materials
3.1.1. Reagents
All o f  the chemicals obtained SIGMA except cisplatin that was obtained from 
BELLON RHONE-POULENC RORER.
3.1.2 Enzymes and enzyme buffers:
S. 1.2.1. PCR enzyme
5u/|il Ampi-Taq DNA polymerase (PERKIN ELMER)
3.1.2. 2. Restriction Enzymes and buffers
25 u/|il M spl (STRATAGENE)
lOx Assay Buffer #2 (For M spl) (STRATAGENE)
10 u/pl Hae III (BOEHRINGER MANHEIM)
lOx SuRe/ Cut Buffer M (For Hae Iff) (BOEHRINGER MANHEIM)
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<1)х174/ H inf I digested 0.5 ng/ml (MBI Fermentas)
100 bp DNA ladder 0.13 pg/pl (PROMEGA)
3.1.4. Commonly used buffers and stock solutions
3.1.4. 1. Büßers and solutions used in PCR
lOx PCR bufFer-MgClz (PERKIN ELMER)
25 mM MgCb solution (PERKIN ELMER)
5 u/pl Ampi-Taq DNA polymerase (PERKIN ELMER)
10 mM dNTPs mix (MBI)
3.1.4.2. Stock solutions required for bacterial tranßormation 
1 M CaClT s^tock solution.
54 g СаСЬ.бНзО was dissolved in 200 ml of dH20. The solution was 
filter sterilised using 0.22 pm filter sterilization unit (COSTAR).
3.1.4.3. Stock solutions required for yeast transformation 
1.0 M LiAc stock solution. pH 8.4-8.9
10.2 g o f lithium acetate was dissolved in 100-ml water, pH is adjusted to 
8.4-S.9.
The solution was filter sterilised with 0.22 pm filter sterilization unit. Solution was 
stored at room temperature.
3 .1 . 3. Markers
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50 g PEG 3350 was weighed out and transferred to graduated beaker, water 
was added until the level just below the 100 ml mark, solution was stirred with 
magnetic stirrer until PEG dissolved. Dissolved solution was transferred in to the 
measuring cylinder and the volume was completed to 100 ml. It was filter sterilised 
with 0.22 pm filter unit and stored at RT in a tightly sealed container.
100 mM LiaC solution
500 pi o f 1.0-M stock solution was diluted in to 4.5 ml o f sterile water.
PEG/LiAc solution (40 % PEG, 100 mM Li Ac)
500 pi o f 1.0 M LiAc stock solution in 500 pi o f sterile water and 4.0 
ml PEG 50 % (w/v) stock solution. Solution was vortexed vigorously for proper 
mixing.
PEG stock solution. 50 % (w M
3.1.4.4. Buffers and stock solutionsfor DNA isolation and Analysis.
3.1.4.4.1. Buffer for isolation o f yeast genomic DNA 
Breaking Buffer 
2 % Triton X-100 
1 % SDS 
100 mM NaCl 
10 mM Tris.Cl pH 8.0 
1 mM EDTA.
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3 M Sodium acetateCl Lt)
408-g sodium acetate.3 H2O dissolved in H2O, pH is adjusted to 5.2 with 3M 
Acetic acid.
3.I.4.4.2. Buffers and solutions used for analysis ofDNA 
TBE electrophoresis buffer lOx stock soln. (1 Lt)
108 g Tris Base 
55 g Boric acid 
40 ml 0.5 EDTA, pH 8.0
0 .5 M E D T A n  Lt)
186.1 g Na2EDTA.2H20 was dissolved in 700 ml dH20, pH was 
adjusted to 8.0 with 10 M NaOH (~50 ml), volume was completed to 1 Lt.
EtBr 10 mg/ml
0.2 g ethidium bromide was dissolved in 20 ml H2O and stored in dark.
Loading buffer 6x (stored at 4°C)
0.25 % Bromophenol Blue 
0.25 % xylene cyanol 
40 % sucrose in water
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3.1.4.5.1. Buffers used for cell lysis and protein extraction under denaturing 
conditions
Laemni Ivsis buffer
50 mM Tris.Cl pH: 6.8 (1.0 M Tris.Cl pH:6.8)
100 mM DTT (1 M stock solution)
2 % SDS ( 10 % SDS stock solution)
20 % Glycerol (v/v)
5 mM EDTA ( 0.5 M  EDTA, pH; 6.8)
1 mM PMSF (1 0  mM PMSF ) Additionally added as protease inhibitor.
3.1.4.5.2. Solutions used for SDS-PAGE
10 % polvacrvamide resolving gel (40 ml)
15.9 ml deionized water 
13.3 ml 30 % Acryamide mix 
10 ml 1.5 M Ir is  (pH:8.8)
0.4 ml 10 % Ammonium per sulfate.
0.0016 ml TEMED
3.1.4.5. Buffers and stock solutions used for selection and testing fo r  p53 expression
5 % stacking polvacrvamide gel (10 ml) 
6.8 ml deionized water.
1.7 ml 30 % Acryamide mix 
1.25 ml l.O M Tris. Cl pH: 6.8 
0.1 ml 10%  SDS
0.1 ml 10 % Ammonium per sulfate
24
Tris-Glvcine electrophoresis buffer (1 Lt) 
25 mM Tris
250 mM Glycine pH: 8.3 
0 .1% S D S
2x SDS gel-loading buffer (Store at 20° C) 
100 mM Tris-Cl (pH 6.8)
200 mM DDT 
4 % SDS
0.2 % bromophenol blue 
20 % Glycerol
3.1.4.5.3. Buffers for Western blot analysis. 
Transfer buffer for Western blot (1 Lt)
5.82 g Tris-base 
3.75 ml 10 % SDS 
200 ml methanol 
2.93 g Glycine
0 .0 1  m l T E M E D
Ponceau S solution HOxl (10 ml)
0.5 g Poncue S was dissolved in 1-ml glacial acetic acid and volume was 
adjusted to 10 ml
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Blocking solution:
5%(w/v) non fat dry milk powder 
0.2 % Tween-20 in PBS
Washing solution
0.3 % Tween 20 (v/v) in PBS
PBS lOx stock solution (1 Lt) pH 7.3
SOgNaCl
2gK C l
l l . 5 gN a 2HPO4.7 H2O 
2  g KH2PO4
Chromogenic visualisation solution:
NBT stock solution (stored at 4°C)
0.5 g o f NBT dissolved in 10 ml o f 70 % dimethylforamide.
BCIP stock solution (stored at 4®C)
0.5 g BCIP dissolved in 10 ml 100 % dimethylformamide
Alkaline phosphatase buffer: 
lOOmM Tris.Cl pH 9.5 
100 mMNaCl 
5mM MgCl2
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3.1.5.1. Media for bacteria 
LB media (1 Lt)
10 gr Trptone
5 gr Bactoyeast extract
lO grN aCI
LB-Amp media
100 jig/ml Amphicillin in LB media
3.1.5.2 Media fo r yeast
YPD (rich medial (1 Lt)
10 g yeast extract 
20 g peptone 
20 g dextrose
20-g bactoagar was added for solid media.
SC media (1 Ltl pH: 5.6-6.0 
6.7 g yeast nitrogen base (without amino acids) 
20 g glucose
20 g bacto agar for solid media
3.1.5. Commonly used media
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3.2 Methods
3.2.1. Strains and Media
3.2.1.1. Bacterial strains and media
E.coli strain D H 5a; F /endAl hsdR ll (r^mk) supE44 thi-1 recAl gyrA 
(Ναι) relAl A(lacIZYA argF) U159 deopR (φ80άΙαοΔ91αοΖ)ΜΙ5) was used for 
bacterial transformation assay. DH5a were grown in standard LB media. 
Transformants were selected and grown in LB-Amp (100 pg/ml amphicillin) media.
3.1.1.2. Yeast strains and media
S.cerevisiae strain AKY28 {Mata, leu 2-2,112, his 3-11, 15, pho3) which is a 
derivative o f GRF18, was obtained from Dr. Akbar Kuchkartaev (Bilkent University, 
Department o f Molecular Biology and Genetics, Ankara, Turkey). M ata is the 
mating type locus where a  mating type genes, M atal and M ata2 are expressed 
(McKay and Manney 1974). leu 2-3, 112 is the non-reverting mutant allele o f LEU2 
that express P-isopropylmalate dehydrogenase (Hsu et al., 1982). his3-l 1, 15 is the 
non-reverting allele o f the HIS3 that express imidazoleglycerol-P dehydratase 
(Struhl, 1982). pho3 is the mutant form of the PH03 that encodes acid phosphatase 
that is involved in thiamine biosynthesis (Nosaka, 1990). AKY28 strain was grown 
in rich YPD media.
Transformed AKY28 cells containing p53-expressing plasmids were selected
in synthetic minimal (SC) media. Specific media was prepared for the induction o f
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gene expression. p53 cDNA was located under the PH05 inducible promoter. 
Several genes encode acid phospatase in a repressible form but the primary gene 
product is derived from the PH 05 gene. PH 05 gene encodes a secreted acid 
phosphotase whose transcription is repressed when yeasts are grown in high 
concentration o f inorganic phosphate (Bajwa et al., 1984). It is induced up to ~ 1000 
fold in response to Pi starvation (Oshima etal., 1982).
The Pi o f normal synthetic SC media is 11.2 mM (1500 mg/liter) is sufficent 
for complete repression . A  Pi o f 0.22 mM (20 mg/ml) is the lowest initial Pi 
consistent with a reasonable growth rate and yield (O’ Connell et ah, 1992).
High Pi and low Pi medium were prepared for repression and induction o f the 
PH 05 promoter. SC media can also be used as high Pi media.
For high Pi and low Pi medium preparation, all the ingredients o f SC media 
were used except bacto-yeast nitrogen base, which contains vitamins, trace elements 
and salts. To obtain high Pi and low Pi medium vitamins, trace elements, and salts 
were prepared separately and filter sterilized with 0.22 pm filter (Costar).
Table 1. Ingredients o f specific media
Amount/Lt
Dextrose
Biotin
Calcium Pantothenate 
Folic acid 
Inositol 
Niacin
20 pg
2 mg 
2 lig  
10 mg 
400 pg
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p-Aminobenzoic acid 200 pg
Pyridoxine hydrochloride 400 pg
Riboflavin 200 pg
Thiamine hydrochloride 400 pg
500 pg
Copper sulfate 40 pg
Potassium iodide 100 pg
Ferric chloride 200 pg
Manganese sulfate 400 pg
Sodium molybdate 200 pg
Zinc sulfate 400 pg
Potassium phosphate monobasic
Magnesium sulfate 
Calcium chloride 
Sodium chloride
r^Dow!iPi;s
1500 mg 20 mg
500 mg 500 mg
100 mg 100 mg
100 mg 100 mg
Potassium chloride 1500 tng
This synthetic medium is based on media described by W ickersham and is marketed as 
‘Yeast nitrogen base without am ino acids’ (Fink and Guthrie, 1991a).
Vitamins and trace elements were stored at 4" C. Salts were stored at room 
temperature. AKY28 is a histine auxotroph. The specific medium also consists 
histidine amino acid. lOOx stock solution o f histidine with a concentration o f 50 
pg/ml was prepared and sterilised using 0.22 pm filter sterilisation unit and stock 
solution was stored at 4 °C. During the medium preparation, ammonium sulfate, 
distilled water and agar added for solid medium were autoclaved together at 122°C 
for 30 Min. Vitamins, trace elements, glucose, salts and amino acid histidine were 
added separately to the autoclaved ammonium sulfate and distilled water under the 
hood. Final solutions named as either high Pi solution or low Pi solutions were also 
kept at 4° C.
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All the plasmid constructs were obtained from Dr. Akbar Kuchcartaev 
(Bilkent university. Department o f Molecular Biology and Genetics, Ankara, 
Turkey). Two plasmid constructs were used. pL3 is the construct that was used as a 
control; it doesn’t contain p53 cDNA, its size is 7.76 kb. pAK31 has human mutant 
p53-248W cDNA and its size is 9.37 kb (Kuchkartayev, A. and Ozturk, M., 
unpublished)
pL3 is 2 |im  circle based episomal plasmid that has 20-40 copy number per 
cell. pAK 31 was derived from pL3 by insertion o f  mutant p53-248W cDNA 
between the PH 05 promoter and terminator. Plasmids contain an ampicillin 
resistance gene as bacterial selectable marker and LEU2 gene as yeast selectable 
marker. LEU2 is one o f the most commonly used yeast selectable marker that 
complement leu 2-3,112 double frameshift mutation . The maps o f the plasmids were 
shown in section 4 (Results) figure 3.
3.2.3. Bacterial transformation
E. coli D H 5a was transformed with plasmids pL3 and pAK31, using calcium 
chloride method (Sambrook et al., 1989a). To prepare the competent cells, a single 
colony was obtained from plate that was freshly grown o/n at 37°C. Then it was 
inoculated to 20 ml LB and grown until its ODeoo value became 0.3-0.4. The culture 
was kept on ice for 10 min. Cells were collected by centrifugation at 4800 rpm for 8 
min. The pellet was resuspended in 1 ml ice-cold 0.1 M CaCb and 200 pi o f
3.2.2. Plasmid constructs
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competent cells were transferred in to eppendorf tubes. After plasmid DNA addition, 
they were incubated on ice for 40 min. For heat shock, they were transferred to a 
42°C circulating water bath for 60 sec. They were then transferred to ice for 1-2 min. 
LB was then added and the cells were incubated for 1 hr in a 37°C water bath. 100 pi 
was taken from eppendorf tubes and spreaded on to LB-Amp plates to select cells 
that were transformed with plasmids; pL3 and pAK31. They were incubated at 37°C 
for 18 hr in incubator until the colonies become visible.
3.2.3. IPlasmid purification
Wizard Plus midiprep DNA purification system ( PROMEGA)was used for 
plasmids purification from pL3 and pAK31 transformed D H 5a cells.
3.2.4. High efficiency transform ation of S.cerevisiae, AKY28 with LiAc.
AKY28 was transformed with pL3 and рАКЗІ using highly efficient LiAc 
transformation. (Gietz, D. R., and Woods, R. A. 1994). Strain AKY28 was grown 
overnight at 30°C in a shaking rotary incubator and 20 pi o f this o/n culture was 
added to 20 ml o f YPD (1/100 dilution) then grown in a shaking incubator until its 
OD value at 600 nm became 0.3-0.4. OD values were detected by spectrophotometer 
fixed wavelength program. (Du 640 spectrophotometer, BECKMAN). Cells were 
harvested by centrifugation at 1500 g for 5 min. Collected cell pellets were washed in 
20-ml sterile water. After second centrifugation, cells were resuspended in 1.0-ml 
sterile dHjO water and transferred to eppendorf tubes and recentrifuged at top speed 
for 10 sec. Collected cell pellets in eppendorf tubes were resuspended in 300 pi o f 
100 mM LiAc. Cells were incubated in a waterbath at 30°C for 15 min. After
32
vortexing briefly, 50-60 |al cell suspension were distributed to eppendorf tubes and 
300 pi PEG/Li solution (40 % PEG, 100 mM Li Ac) were added to each tubes. 
Incubation o f transformation eppendorf tubes in a waterbath at 30"C for 30 min was 
followed by heat shock at 42°C for 20 min. PEG/LiAc solution was removed by 
microcentrifugation at high speed for 10 sec. The cells were washed by 1.0 ml o f 
sterile dH2 0  and diluted 100 times. 100 pi samples o f dilutions were spreaded on to 
the SC selective medium without amino acids. Plates were incubated for 3-4 days at 
30°C in incubator. After transformed yeast strain were obtained, immediately their 
glycerol stocks were prepared. For glycerol stock preparation 1 ml o f transformed 
yeast cells were grown in selective media (SC) until saturation or late log phase, and 
1 ml 30 % glycerol were mixed with the saturated cell suspension. Stocks were 
stored at -80" C.
3.2.5. Analysis of purified plasmids from bacteria and from genomic 
yeast DNA to test the state of p53 with PCR and restriction enzymes.
p53 mutant-248W containing plasmids purified from plasmid transformed 
bacteria DH5a and AKY28 yeast cells that were transformed with those plasmids 
were analysed by PCR and restriction enzymes to confirm the state o f  p53.
For analysis o f p53 state from pL3 (without p53 cDNA insert) and 
pAK31(p53 mt-248W p53 cDNA insert) transformed AKY28 cells, total yeast 
genomic DNA was isolated from transformed yeast cells (Ausubel et al., 1987b). For 
total yeast genomic DNA isolation, 2-ml culture o f AKY28 cells carrying the 
plasmids pL3 and pAK31 were grown to stationary phase in SC media, the liquid 
should be visibly turbid and pellet o f the cells should have accumulated at the bottom
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o f the tube. 1.5 ml o f the saturated culture were transferred in to a microcentrifuge 
tube and centrifuged 5 sec at room temperature. The supernatant was poured off and 
cells were resuspended in 200 pi breaking buffer. The crystal beads were added just 
below the meniscus o f the cell suspension and the mixture o f beads and cell 
suspension were mixed by vortexing at max speed for 60 sec, tubes was placed on 
ice for 1-2 min on ice. This step was repeated three times. Then 200-pl o f 25:24:1 
phenol/chloroform/isoamyl alcohol (PCI) was added and tubes were mixed by 
vortexing at max speed like previously done. The DNA containing mixture was 
centrifuged at max speed for 5 min at room temperature. The upper aqueous phase 
was transferred to another tube and one more 200 pi PCI was added and mixed by 
vigorous vortexing for further purification from proteins and solute molecules. For 
phase separation the tubes were centrifuged at max speed for 1 min at room 
temperature. The top aqueous phase containing DNA was transferred to another 
eppendorf tube containing 100 % ethanol that contain 1/10 vol o f 3 M sodium acetate 
(If 200 pi DNA aqueous phase was collected, 20 pi from 3 M sodium acetate was 
added). Mixture o f DNA aqueous phase, 100 % ethanol and sodium acetate were 
mixed by vortexing and kept at -20° C for at least 30 min for precipitation o f DNA. 
After precipitation step the eppendorf tubes were centrifuged at max speed for 10 
min which was followed by aspiration of 100 % ethanol, either with pipetting or 
pouring off. For washing step 1-ml o f 70 % ethanol was added. Tubes were inverted 
several times and spinned in microcentrifuge tubes. Supernatant was aspirated 
carefully by pipetting. The pellet was dried under the lamp. After the ethanol 
completely removed, the pellet was dissolved in 40-pl dd H2O. The concentration o f 
obtained DNA was detected using the DNA/oligo quant, double strand DNA 
program o f  spectrophotometer (Du 640 spectrophotometer, BECKMAN)
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To test the state o f p53 at DH5a purified plasmids and plasmid transformed 
AKY28 yeast cells, 110 bp fragment that coiresponds to exon 7 o f mutant p53-248W 
sequence was amplified with PCR (PERKIN ELMER Gene Amp PCR system 2400).
3.2.5.1. Amplification o f 110 bp fragment o f exon 7 ofp53 cDNA with PCR
To analyse purified plasmids and transformed AKY28, 110-bp fragment o f 
exon 7 o f the p53 cDNA sequence was amplified with PCR.
Table 2.The sequence of 110-bp fragment at exon 7 and localisation o f 
primers on it.
F3
ÏCATCCA CTACAACTAC
ATGTGTAACA GTTCCTGCAT GGGCGGCATG AACCGGAGGC
CCATCCTCAC cagg
R3
Primers F3 (5’ -GTTGGCTCTGACTGT ACC AC-3) and R3 (5’ - 
CTGGAGTCTTCCAGTGTGAT- 3 ) were used. The primers were synthesised at 
Department o f Molecular Biology and Genetics o f Bilkent university with 
oligosynthesizer (OLIGO lOOOM BECKMAN). For 50 pi PCR solution; 5 pi 1 Ox 
PCR buffer- MgCla, 1.5 mM MgCl2(25 mM stock solution), 200 pm dNTP mix (10 
mM stock solution), 25 ng plasmid DNA, for amplification from yeast DNA, 100 ng 
total yeast DNA, 10 pmole from each primer, 1 unit Taq polymerase (5 u/pl) were 
used. PCR was performed by using Perkin Elmer Gene Amp PCR system 2400. PCR 
was programmed as; 30 cycle including; 95**C 30 sec for dénaturation, 55 °C 30 sec
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for annealing, 72 °C 30 sec for extension; initial cycle include one hold at 95°C for 3 
min for initial denaturing and final cycle include three hold at 72° C for 10 min for 
final extension.
3.2.5.2. Purification qfPCR products
Ingredients o f PCR might effect the further assays like restriction enzyme 
analysis. To prevent this problem, PCR products were purified using QIA quick PCR 
purification kit (250).
3.2.5.3. Analysis o f PCR amplifiedfragment in agarose/NuSieve Agarose gel 
electrophoresis.
Due to size o f the fragment, both PCR products and restriction enzyme 
digested fragments were analysed using 2% Agarose + 2 % Nu Sieve agarose 
dissolved in TBE buffer.
3.2.5.4. Restriction enzyme analysis o f PCR amplified 110-bp p53 cDNA fragment 
that contains mutant p53 sequence (codon 248, R->W).
It is known that mutant p53 sequence (codon 248, R->W) can be 
differentiated from wild type by restriction enzyme analysis because a specific 
restriction enzyme site present on wild type is lost when there is a mutation at codon 
248 or 249. 248*’’ codon o f the p53 corresponds to the nucleotide sequence CCGG, at 
mutant p53 sequence (codon 248, R->W), the nucleotide sequence change to CTGG. 
Recognition sequence o f Msp I is CC>1'GG. At mutant p53 sequence (codon 248, R- 
>W) this site was disappeared and digestion o f Msp 1 did not occur. After the 
presence o f a mutant p53 sequence (codon 248, R->W) in pAK31 vector was
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verified, this vector as well pL3 as control were transfected to AKY28 strain. 
AKY28 cells that were transformed with those plasmids were also analysed to test 
the existence o f mutant p53 sequence (codon 248, R->W) with restriction enzyme 
analysis. Conditions for Msp 1 digestion was as following; for 25 pi total volume, 
2.5 pi from lOx assay buffer #2, 8 pi from PCR product (amount that was loaded to 
agarose gel) 1 pi o f 25 u/pl Msp 1 restriction enzyme, and 13.5 pi dd H2O.
Beside Msp 1, Hae III enzyme was used. Hae III recognises the sequence 
GG'l'CC that corresponds to the 249^  ^amino acid of p53. The mutant p53-249(W) is 
one o f the commonly detected p53 mutations in human cancers (Bressac et al.,
1991). In the case o f mutant p53 sequence (codon 249, R->S) mutation, that 
correspond to wild type p53 sequence, GGCC change to GTCC that loses the Hae III 
recognition site. Mutant p53 sequence (codon 248, R->W) that we used in this 
experimental system, conserves this sequence so beside wild type p53, Hae III is also 
able to digest mutant p53 sequence (codon 248, R->W). Conditions of Hae III digest 
for 25 pi total volume include; 2.5 pi o f lOx SuRe cut buffer M, 13.5 ml o f dd H2O,
8 pi from purified PCR product, and 1 pi o f 10 u/pl Hae III restriction enzyme.
During the experiments pC53-SN (wild type p53 sequence insert) and 
pCMVp53-249 (mutant p53 sequence (codon 249, R->S) insert) were used as control 
plasmids. 110-bp fragment was also amplified from those pladmids with PCR and 
digested with Msp I and Hae III.
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p53 expression in yeast was analysed using Western blot analysis. For 
Western blot analysis, cells were lysed and proteins were extracted under denaturing 
conditions.
3.2.6.1. Cell lysis and protein extraction under denaturing conditions
For cell lysis and protein extraction (Louise et al., 1994); 15 ml o f cells were 
precipitated and the pellet was washed with ice cold sterile water. Cells were 
resuspended in 150 pi Laemni lysis buffer. Crystal beads were added to the level o f 
the meniscus and mixture o f bead and cells were vortexed at max speed for 60 sec, 
tubes were placed on ice for 1-2 min on ice. This step was repeated five times or 
more, until nearly 90 % o f the cells lysed. Lysis o f cells can be examined under the 
light microscope with lOx magnification. By centrifugation, supernatant that contains 
crude cell extract was collected in to another tube. To obtain more cell lysate and to 
wash the beads, one more 150 pi Laemni lysis buffer was added and the steps were 
repeated. Collected supernatant was pooled in to eppendorf tubes (Loison, 1994b).
3.2.6.2. Determination o f protein concentration
Due to interference o f lysis buffer with Bio-Rad assay kit, protein 
concentrations were determined using the following formula (Marshak et al., 1996); 
Protein concentration (mg/ml) = [1.55 A280 -0.76 Ajeo] x DF 
DF: Dilution factor
3.2.6. Selection and testing for p53 expression
38
Western blot analysis was applied after solubilization o f proteins and their 
separation by SDS-PAGE (Sambrook et al.,1989b)
Between the size range 14-66 IcDa, optimal percent o f acrylamide gel is 8- 
10%. For 53-kDa p53 protein 10% resolving gel was preferred and as stacking gel 
5% polyacrylamide gel was used.
SDS-page was runned at 80 V for 12-18 hr and as running buffer Tris- 
Glycine electrophoresis buffer was used.
For Western blot analysis, proteins on the SDS-PAGE were 
electrophoretically transferred in a semi-dry electrophoretic transfer cell. Before 
blotting, resolving gel and PVDF were equilibrated at room temperature for 15-30 
min in transfer buffer.
The semi dry system was placed as follows; two 3MM whatman papers 
prewetted in transfer buffer were inserted at the bottom which was cathode part of 
the semi-dry unit and PVDF paper was placed on them, gel is placed on top o f the 
membrane, the transfer stack was completed by putting two 3MM whatman paper on 
it. Air bubbles were prevented between the gel, membrane and 3MM whatman 
papers by gentle rolling with a test tube. The cell were runned for 1 hr at 12 V. After 
the transfer was complete, PVDF paper was removed and washed with Ponceau S 
solution for 5 min at room temperature. Ponceau S staining was followed by 
destaining with water to mark the sites o f molecular weight standards. For 
quantification of immobilised proteins probed with specific antibodies, PVDF paper 
was immersed in blocking solution for 30 min to 1 hr at room temperature with 
constant agitation to fill all protein binding sites. For probing o f p53 proteins with
3.2.6.3. Analysis o f proteins in crude cell lysates by western blot
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specific antibody, blocking solution was replaced with lOOOx diluted primary 
antibody HR231 (ascites fluid) (a gift from T. Soussi, Institude Curie, Paris, France) 
in blocking solution and was incubated at room temperature for at least 1 hr with 
constant agitation. For additional studies the following anti-p53 monoclonal 
antibodies against different epitopes of the p53 protein were used; 7F4, 9E4, 
pAb240, H53C1, H53C2, H53C3, and pAbl22 (ATCC). Hybridoma supernatants 
were used at a 1/10 dilution and ascites fluids were used at a 1/1000 dilution. The 
blot was washed with four changes o f washing solution for 5 min each. Then anti 
mouse alkaline phosphatase antibody conjugate was added which was (SIGMA) 
diluted in blocking solution (1/35000 dilution ratio). This step followed by 1 hr 
incubation at room temperature with constant agitation. After following washing step 
that included four changes o f washing solution for 5min each, the PVDF membrane 
was placed in 5 ml alkaline phosphatase buffer containing BCBP/NBT (33 pi NBT 
from NBT stock solution, 17 pi BCIP from BCIP stock solution) for visualisation o f 
the p53 protein (Harlow and Lane, 1988).
3.2.7. Application of DNA damaging agents
3.2.7.1. UV-C treatment
UVC (254 nm) irradiation was carried out using UV crosslinker (stratalinker, 
STRATAGENE). For UV irradiation o f cells; 10 ml liquid medium like YPD, SC or 
specific high Pi or low Pi medium was inoculated with a freshly subcloned sample o f 
the yeast strain to give approximately lx  10  ^yeast cells/ml that corresponds to 1/100 
dilution. The culture was incubated until it’s OD value at 600 nm became 0.5 (nearly 
mid-log phase which is the phase most sensitive to DNA damage due to high cell
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division rate). When absorbance o f cell suspension reaches to 0.5 at OD 600 nm, 
there are about 1.5x 10  ^cells/ml. The cells were washed in sterile water and they 
were irradiated either on plates or in liquid suspension, according to the assay type. 
For cell survival assay, irradiation was exposed on solid media after serial dilutions 
o f  cells were applied to the surface o f agar media in petri plates and for p53 protein 
level analysis upon DNA damage, irradiation in cell suspension was preferred 
(Ausubel et al., 1987a; Fink and Gutrie, 1991b). The optimal dose o f UV was 
selected according to survival assay o f yeast cells and this dose was applied for 
further protein assays.
3.2.7.2. Cisplatin treatment
As a second DNA damaging agent, cisplatin was used. Cisplatin as DNA 
damaging agent in S.cerevisiae was used at previous studies (McA’ Nulty et al., 
1996a, M cA’ Nulty et al., 1996b). The protocol o f cisplatin treatment was derived 
from these studies.
Experimental procedure including cell growth, collection of cells and 
washing with water followed by UV-C treatment was nearly same for cisplatin 
treatment. Only the exception is, the cells were resuspended in cisplatin containing 
specific liquid medium for p53 protein response upon DNA damage which was 
detected by Western blot and, for cell survival assay, cells were grown in cisplatin 
containing plates.
100 mM cisplatin stock solution was prepared, by dissolving cisplatin (MW 
300 g/mole) in dHjO. Small amount o f aliquots was prepared for daily use and they 
were kept at 4"C. The optimal cisplatin concentration was found according to cell 
survival assays and this dose was applied for further protein assays.
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After cells were grown in specific media (either high Pi salt containing or low 
Pi containing m edia) up to the their ODeoo value became nearly 0.5, cells were 
pelleted and resuspended in water to a density o f 2 x 10  ^cells/ml. Tenfold serial 
dilutions o f each pL3 transformed and mutant p53-248W transformed AKY28 yeast 
cells were prepared and lO-pl aliquots o f the undiluted and diluted samples were 
spotted on plates.
For UV treatment after spotted colonies were incubated on plates for a time 
period (incubation time before UVC treatment optimised), the plates were exposed 
and unexposed as a control to the different doses o f UVC light using a UV 
crosslinker that change between 50 j/m^-150j/m^. The controls were exposed to UV 
light at all. Plates were photographed after 2 days and 3 days o f growth at 30°C 
incubator.
For cisplatin treatment, lO-pl aliquot o f the undiluted and diluted samples 
were spotted on plates containing different concentrations o f cisplatin, ranging from 
0.5 to5 mM.
3.2.7.3. Cell survival assc^
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4. Results
Our aim was to establish an experimental model to study wild type and 
mutant human p53 protein effects in yeast cells. As yeast cells do not produce p53 
protein, we based our experimental system on yeast cells stably expressing human 
p53 proteins. We decided to use mutant form o f p53-248W for the initial step o f this 
long-term project. 248(R->W ) is one o f the most frequently altered residue in the p53 
protein, result in defective contacts with the DNA and loss o f the ability o f  p53 to act 
as a transcription factor (Cho et al., 1994). Yeast expression vectors allowing 
regulated expression o f  p53 were constructed prior to our work. These vectors 
contain human p53 coding sequence under the control o f Pi regulated PH 05 
promoter. In this work we used pAK31 plasmid that express human mutant p53- 
248W. As a control pL3 with no insert was used. We decided not to use a wild type 
p53 expressing vector during the establishment o f this experimental system because 
o f the reported growth inhibitory activity o f  p53 protein in yeast cells (Bischoff et al., 
1992; Nigro et al., 1992).
As a first step, we verified the presence o f a mutant p53 sequence (codon 
248) in pAK31 vector. Then this vector as well as pL3 control were transfected in to 
AKY28 strain yeast cells and stable colonies were selected in the Leu' medium.
These cells were first tested for the expression o f mutant p53-248W protein.
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After demonstrating Pi regulated expression o f mutant p53-248W protein, we then 
compared the growth rate of cells transfected with pAK31 and pL3. Next, different 
cell lines (expressing and non-expressing mutant p53-248W) were tested for UV-C 
and cisplatin induced DNA damage and cell survival. p53 protein levels in UVC and 
cisplatin-treated cells.
Human mutant p53 (codon 248, R->W) cDNA sequence together with 
sequences including nucleotides from -17  to +12 (relative to tranlation start site and 
stop codon respectively) between the Pi repressible PH05 promoter and terminator 
was subcloned in to the Sal I and Hind III site of the pL3 plasmid for the construction 
of pAK31 plasmid (Fig 3) (Kuchkartaev, A.and Ozturk, M.unpublished)
EcoRI 7.75
pL3 
7.76 kb
Fig. 3. Map of the control plasmid pL3
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Sma 1 
Kpn1 
Sac 1
.CCG =>TGG 0.86
EcoR1 1.62
PstI 7.48
EcoRI 6
Kpnl6.17
PstI 5.31 I EcoRI 5.09 
Stul5.17
;P PH05 clal 1.87
BamHI 2.14
SphI 2.31 
Sail 2.40 
Styl3.12
Ball 3.19 
Puvl 13,42 
Ndel 3.65
pAK 31 
9 .37 Kb
Fig.3. (Cont’d). Map o f the plasmid pAK 31 (mutant p53-248W cDNA)
The constmcted pAK31 plasmid contains ampicillin'^ gene as selectable 
marker in bacteria and LEU2 gene as selectable marker in yeast. LEU2 gene encodes 
P-isopropylmalate dehydrogenase that complements Leu 2-3, 112 mutation. The 
tetracycline resistance gene (Tc) found in pL3 plasmid is not found pAK31 due to 
insertion o f mutant p53 sequence between PH 05 promoter and terminator. 
Transcription from the PH 05 promoter is repressed when cells are grown in high Pi 
medium and depressed in low Pi medium.
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4.1. Verification of mutant p53 sequence (codon 248) in pAK3l vector and 
pAK31 transfected AKY28 yeast cells.
Plasmids pL3 (without p53 cDNA insert) and pAK31 (mutant p53-248W 
cDNA insert) were purified from DH 5a transformed cells using Wizard midi prep 
purification kit. The concentration o f plasmids were determined using the DNA/oligo 
quant single strand DNA program (Du 640 Spectrophotometer BECKMAN). For 
analysis o f mutant p53 sequence (codon 248), a 110-bp fragment o f p53 exon 7 that 
contains 248 mutant site was amplified with PCR. After PCR amplification the PCR 
products were purified using QIA quick PCR purification kit. Purified PCR products 
were analysed in 2 % agarose/ 2% Nusive agarose gel ( Fig. 4)
op
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Fig. 4. Results o f PCR amplification o f 1 lO-bp fragment obtained from pAK 31 plasmid. 110 
bp DNA maricer was used. Negative indicates tlie PCR reaction vvitliout D N A  Control is tlie 
PCR amplified 200 bp fragment, Mt-248-1,2,3 indicates pAK 31 isolated from three colonies 
o f  transformed DH5a bacteria cells.
The amplified 110-bp fragment obtained from mutant p53 sequence (248
codon, R->W) was digested with restriction enzymes. The nucleotide sequence at
248 *** codon o f wild type p53 corresponds to CCGG which is the sequence
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recognised by the restriction enzyme Msp 1 (C 4^CGG). In the mutant p53 sequence 
(codon 248, R->W), the second nucleotide is replaced by a T nucleotide that destroys 
Msp 1 recognition site. Thus Msp 1 is able to digest the wild type p53 c DNA but 
unable to digest the mutant p53 sequence (248 codon, R->W). In addition to Msp 1, 
Hae III was also used for digest analysis. Hae III recognises the sequence GGCC.
The mutant p53 sequence (codon 249, R->S) is one o f the commonly detected p53 
mutations in human tumours (Bressac et al., 1991). In the case o f this mutation 
GGCC changes to GTCC. The recognition sequence o f Hae III enzyme (GG^^CC) is 
destroyed in the mutant p53 sequence (codon 249,R->S). Hae III digests both the 
wild type p53 sequence and the mutant p53 sequence (codon 248, R->W) that 
conserves recognition sequence o f the enzyme. Msp 1 digestion o f 110-bp fragment 
amplified from wild type p53 sequence yields 68-bp and 42-bp fragments and Hae III 
enzyme digestion yields 75- and 35-bp fragments.
Msp 1 digestion o f 110-bp fragment amplified from the mutant p53 sequence 
(248 codon, R->W) plasmid, pAK31, yielded an undigested 110-bp fragment. Hae IE 
digestion yielded 75- and 35-bp fragments. As control wild type p53 sequence and 
mutant p53 sequence (codon 249, R->S) were amplified from control plasmids 
pC53-SN (wild type p53 sequence insert) and pCMVp53-249 (mutant p53 sequence 
(codon 249, R->S) insert) respectively were also digested with Msp 1 and Hae III 
(Fig.5).
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W tp53  249M  248M -1 248M -2 248M -3
a® 8 s m Bsa; gsK Bs
Fig. 5. Msp 1 and Hae III digestion o f 110-bp fragment amplified from mutant p53 sequence (codon 
248, R->W) in pAK 3 Ivector. As control pL3, 249M, and Wt p53 were used. Wt p53 and M249 were 
amplified from wild type p53 and mutant p53 sequence (codon 249, R->S) containing plasmids pC53- 
SN and pCMVp53-249 respectively. UD represents undigested, 110 bp fragment. Blue arrow 
indicates undigested 110 bp fragment, pink arrows indicate Msp I digestion products 68 bp and 42 bp 
fragments, red arrow indicates Hae III digestion products 75 bp and 35 bp fragments.
pAK 31 yeast expression vector containing the mutant human p53-248W and 
control vector pL3 were used for the transformation of AKY28 (M ata, Leu 2-3,112, 
pho3) yeast strain. High efficiency LiAc transformation protocol was performed 
(Johnston, 1994). After transformation with the LEU2 containing plasmids, pL3 
(without p53 insert) and pAK31 (mutant p53 sequence (codon 248, R->W) insert), 
AKY28 cells were grown on Leucine deficient SC medium. The transformed 
colonies were obtained after 3-day incubation at 30 “C. Three colonies were selected 
from transformed AKY28 for restriction enzyme analysis. Total yeast DNA was 
isolated using the rapid DNA isolation protocol (Sambrook e /a /., 1989b) to analyse 
the p53 state in the transformed AKY28 cells. The 110 -bp p53 sequence was 
amplified from the total yeast DNA using the same primers and PCR conditions.
PCR products were analysed in 2% agarose/ 2% NuSieve agarose gel. As marker, 
(j)xl74/ Hinf III was used (Fig.6).
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Marker Mt-1 Mt-2
110 bp
Fig. 6. Results o f PCR amplification of 110 bp sequence from exon 7 o f p53 cDNA obtained 
from mutant p53 expressing yeast cells. pL3 without insert was used as a control. Two 
colonies of pAK31 transformed AKY28 cells were selected for PCR amplification, mt-1 and 
mt-2 indicate 110 bp tliat was amplified from total DNA of those colonies.
After thel 10 bp fragment was amplified, it was digested with Msp 1 and Hae 
III restriction enzymes. The results of digestion were examined at 2 % agarose and 2 
% NuSuive gel. As a marker, (|)xl74/ Hinf I was used. As a control, Msp I and Hae 
III digested wt p53 cDNA sequence and mutant p53 sequence (249 codon, R->S) 
were amplified from control plasmids pC53-SN (wild type p53 sequence insert) and 
pCMVp53-249 (mutant p53 sequence (codon 249, R->S) insert). Following Msp 1 
digestion o f mutant p53 sequence (codon 248, R->W), an undigested 110 bp 
fragment was obtained. Hae III digestion o f mutant p53 sequence (codon 248, R- 
>W) yielded 75- and 35-bp fragments like the Hae III digested wild type p53 
sequence (Fig.7).
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WTp53 249M 248M-2
Fig 7. Msp land Hae III digestion of 110-bp fragment obtained from mutant p53 expressing yeast 
cells. 248M-1 and 248M-2 were digestion products o f amplified mt-1 and mt-2. Wt 53 and 249M 110 
bp DNA fragments were obtained from control plasmids pC53-SN (wild type p53 sequence insert) 
and pCMVp53-249 (mutant p53 sequence (codon 249, R-> S) insert) respectively. UD indicates 
undigested 110 bp fragment. Blue arrow indicates undigested 110 bp fragment, pink arrow indicates 
Msp I digestion product 68 bp and red arrow indicates Hae III digestion product 75 bp.
4.2. Western blot analysis of mntant p53-248W protein expression in 
AKY28 cells
Mutant p53-248W protein expression in AKY28 strain yeast cells was shown 
by Western blot analysis. Initially pL3 and pAK31 transformed cells were grown in 
high Pi (for PH 05 repression) and low Pi medium (for PH 05 induction) to stationary 
phase (~ 30 hr incubation at 30 °C) until the medium became visibly turbid and a 
pellet o f cells accumulated at the bottom o f the tube. Total protein was extracted 
under denaturing conditions from each cell suspension. The concentration (mg/ml) o f 
proteins was calculated using the formula: 1.55 A280- 0.76 Ajeo- For SDS/PAGE 150- 
pg protein was applied per well. The proteins were separated on an SDS- 
polyacrylamide gel, transferred to PVDF menbrane (Millipore), and then reacted 
with antibodies against different epitopes o f p53 (Table 3) (Fig. 8)
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HR231 C terminus Bartek et al., 1993; Legros et al., 1993.
7F4 central Yolcu. E., Yurdusev, N. and Oztiirk, M. 
(unpublished)
9E4 central Yolcu, E., Yurdusev, N. and Oztiirk, M. 
(unpublished)
H53C1 central Vaultzel, T. and Oztiirk, M. 
(unpublished)
H53C2 central Vaultzel, T. and Oztiirk, M. 
(unpublished)
H53C3 central Yolcu, E., Yurdusev, N. and Oztiirk, M. 
(unpublished)
pAb 240 central Gannon et al., 1990, Stephan et al., 1992
pAbl22 C-terminus Gurney et al., 1980; Wade, A. and 
Jenkins, J. R., 1985.
Table· 3· Murine monoclonal anti-p53 antibodies against different epitopes o f p53.
m r-H
'w' u <N
Ph
m
2 w
CNX)
<
CO oCOI/Or> X
m
Umin
(N(NT-H
<
.J ' I','! , ·„</'·' 1
■mutant p53 
'  protein
Fig. 8. Demonstration of p53-248W protein expression in yeast using different anti-p53 monoclonal 
antibodies.
Best results were obtained with HR231 and it was routinely used for Western 
blot analysis.
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Mutant p53-248W was detected in yeast cells transfected with pAK31, but 
not pL3. p53 was detected cells grown in both high Pi and low Pi media. Although 
protein levels were higher cells in low Pi medium compared the high Pi medium, the 
expression was leaky under high phosphate condition, suggesting that PH05 
promoter was not totally suppressed in high Pi medium. (Fig.9)
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Fig .9. The results of western blot analysis, mutant p53-248W protein expressed in low Pi and higli Pi 
medium. Mt-248-1,2,3 represents the mutant p53-248W protein tliat was purified from tliree AKY28 
colonies that were transfected with pAK31.
PH 05 promoter induction is regulated by Pi concentration. For maximum 
induction o f the PH 05 promoter, cells have to reach the post-exponential phase for 
Pi starvation (Cartwright ei al., 1994). The expression o f p53 in yeast cells grown in 
high Pi and low Pi containing medium using different incubation times 24 hr, 48 hr, 
and 72 hr. We also measured Western blot analysis of p53 protein at different 
incubation times. The results were indicated that 24-hr incubation was sufficient for 
PH05 promoter induction and subsequent p53 expression (Fig. 10).
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Fig.lO. Analysis o f p53 expression at 24*. 48*, and 72* hr incubation in both high Pi and Low Pi 
medium. Mt248-1, 2, 3 indicate mutant p53-248W extracted from three different colonies of pAK31 
transformed AKY28 cells.
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4.3. Effect of mutant p53-248W protein expression on growth rate of the yeast 
cells
After mutant p53 expression was shown in high Pi and low Pi medium, the 
effect o f mutant p53 on yeast cell survival was examined. The growth-inhibitory 
effect o f p53 has been examined previously. It was reported that colony growth 
differed among the cells expressing wild type p53, mutant p53, and no p53 (Bischoff 
etal., 1992). After transformation o f yeast cells, no difference was detected in the 
colony size and growth rate o f the cells expressing and control cells (Fig. 11). An 
experimental system was designed to study mutant p53 growth effects in yeast. This 
system was also used for further studies including p53 growth effects upon DNA 
damaging agents in yeast. For p53 growth effect assay the pL3 and pAK31 
containing yeast cells were grown at high Pi and low Pi medium until their OD value 
at 600 nm reach 0.5. The cells at this density were pelleted and resuspended in water 
to a density o f  2x10^ cells/ ml. Tenfold dilutions o f  each were prepared and lO-pl 
aliquot o f the undiluted and diluted samples were spotted on plates containing high 
Pi and low Pi agar medium. Then the plates were incubated for 3 days at 30° C. This 
assay was performed in one petri plate to examine p53 effects on cell growth clearly. 
According to this analysis no difference was detected in growth phenotypes between 
the yeast cells expressing mutant p53 protein and control cells.
54
10'
10'-
10'
10'
10'
10"
F ig .ll. Effect o f mutant-p53 expression on growth rate o f yeast cells. I indicates non- mutant 
p53 expressing yeast cells, II, III, IV indicate mutant p53 e.xpressing yeast cells.
4. 4. Establishm ent of an experimental model to evaluate the role of p53 
in yeast after DNA damage.
For cell survival assay after DNA damage, pL3 and pAK31 containing yeast 
cells were grown at high Pi and low Pi medium until their OD value at 600 nm reach 
0.5. Tenfold dilutions o f each were prepared and lO-p. 1 aliquots o f the undiluted and 
diluted samples were spotted on plates containing high Pi and low Pi agar medium. 
Before UVC treatment the plates were incubated for 24 hr at high Pi and Low Pi 
medium to allow expression o f the mutant p53 protein. Then the cells were exposed 
to different doses of UVC light in the range between 50 j/m^ and 150 j7m^. After UV 
exposure, plates were incubated for 2 more days at incubator at 30°C and then they 
were photographed. The results o f UV survival data showed no decrement o f 
survival in any of these cell lines after 24-hr incubation when high doses were
applied. Following observation, cells were incubated fori 8 hr instead o f 24 hr at 
30°C before UV exposure (Fig. 12),
High Pi
1 2  3 4 
150 j/m2
Fig.l2. Survival assay o f PL3, pAK31 transformed AKY28 yeast cells.
(a) AKY28 yeast cells transformed witli PL3, pAK31 tliat grown on the high Pi medium (b) 
AKY28 yeast cells transformed with PL3, pAK31 that grown on the low Pi medium. UVC 
was applied after 18 lu· incubation at 30°C. I indicates pL3 transformed yeast cells. II, III and 
IV indicate tluce colonies of pAK31 transformed AKY28 yeast cells.
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Low Pi
100 j/m 150 j/m
Fig. 12 (Cont’d). Survival assay o f PL3, pAK31 transformed AKY28 yeast cells.
Yeast cell survival analysis indicated that 18 hr incubation prior to UVC 
exposure was sufficient to observe the killing effect o f radiation. Survival curve o f 
mutant p53-248W expressing yeast cells after UVC radiation are shown in Fig. 13. 
The survival assay o f mutant p53 expressing (pAK31 transformed) and non­
expressing (pL3 plasmid transformed) AKY28 cells that were grown in both high Pi
and low Pi medium did not exhibit any detectable difference so that survival curves
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of mutant p53 expressing and non-expressing yeast cells were same. Both cells 
showed the same sensitivity to UVC-radiation. Also no growth difference was 
detected among the mutant p53 expressing and non-expressing cells that were not 
exposed to UVC radiation.
Fig.l3. Survival curve o f mutant p53 expressing yeast cells in low Pi medium.
4.5. Western blot analysis of mutant p53 expression after UVC radiation 
of yeast cells.
For Western blot analysis, yeast cells were irradiated in suspension rather 
than on solid agar. Depending on cell concentration, cell suspensions significantly 
absorb and scatter UV. Suspensions therefore need to be exposed to higher UV doses 
then cells on plates. For this reason, 100 J/m^ UV was applied to the yeast cell 
suspension in 10-ml water in a plate. At various time points (4 h, 8 h, and 24 h) 
following irradiation, cells were examined for p53 expression. Immunprecipitation of 
mutant p53 protein with anti-p53-monoclonal antibody, HR231 did not show any 
difference in the p53 protein levels at those post-radiation time points (Fig. 14).
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protein
Fig. 14. Western blot analysis o f mutant p53 protein at various time points (4 h, 8 h, and 24 h) 
following UV-radiation. Yeast cells were grown m liigh Pi medium. 248 Mt-1, 2, and 3 indicate 
mutant protein obtained from tliree colonies of pAK31 transfonned yeast cell
4.6. Effect of mutant p53 on yeast survival upon another DNA-damaging 
agent cisplatin treatment.
The effect o f mutant p53 on yeast cell survival was analysed with another 
DNA damaging agent, cisplatin. For cisplatin treatment, cells were grown in low Pi 
medium to saturation. Tenfold serial dilutions were prepared and 10 |il aliquots of 
the diluted and undiluted samples were spotted on plates containing 0.5 mM, 1 mM,
3 mM, and 5 mM cisplatin dissolved in low Pi agar medium. Plates were incubated 
for 3 days at 30“C and then the plates were photographed using image analyser under 
the visible light. The survival effect o f different cisplatin concentrations was 
analysed at the end o f third day o f  incubation. The killing effect o f cisplatin was
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detected at 0.5 mM. At 3mM and 5 mM cisplatin concentrations, the killing effect 
was highly inreased (Fig. 15).
C ontrol
1 2 3 4  
0.5 m M
Fig. 15. Survival assays o f mutant p53 e.xpressing yeast cells upon different concentration of cisplatin, 
0.5 mM, 1 mM, 3 mM, and 5mM in liigli Pi and low Pi medium. 1 indicates pL3 transformed yeast 
cells. 2, 3 and 4 indicate tlrree different colonies of AKY28 cells that were transformed with pAK31.
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According to survival curve o f  mutant p53-248W protein expressing yeast 
cells to different cisplatin concentrations (Fig. 16), no difference was detected 
between mutant p53 expressing and control yeast cells. Both o f them have the same 
survival curve.
Fig.l6. Survival curve for the mutant p53 expressing yeast cells. Cisplatin concentration in low Pi 
medium ranged between 0 mM to 5 mM intervals.
4.7. Western blot analysis of mutant p53-248W expression in yeast cells 
that were grown in different concentrations of cisplatin containing medium.
After testing the effect o f mutant p53 on yeast cell survival after exposure to 
DNA damaging agent cisplatin, the mutant p53 protein levels were analysed. AKY28 
yeast cells were grown in different cisplatin concentration (0.5 mM, 1 mM, 2.5 mM,
5 mM, and 10 mM) containing low Pi medium for 24 h. The cells were lysed and 
total protein was extracted under denaturing conditions using Laemni lysis buffer.
For Western blot analysis the primary antibody HR231 was used. No significant 
differences were detected in mutant p53-248 protein expression among the cells that 
were grown in different cisplatin concentration. More importantly, there was no
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increase in mutant p53 protein level following cisplatin induced DNA damage 
(Fig. 17).
mutant p53 protein
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Fig. 17. Western blot analysis o f mutant p53 expression anrong tlie cells that were grown in 
diiferent cisplatin concentration.
4. 8. Western blot analysis of mutant p53 expression upon UVC and cisplatin 
treatment among the AKY28 cells that were grown in high Pi medium.
Mutant p53 expression in yeast cells exposed to different doses o f UV- 
radiation and cisplatin concentrations in low Pi medium was also analysed. Previous 
mutant p53 expression analysis indicates that constructed PH05 promoter is a leaky 
promoter which is not completely suppressed in high Pi medium. Although mutant 
protein was also expressed under high Pi conditions, a small difference was detected 
compared to mutant p53 expression in low Pi medium. Considering this difference, 
mutant p53 expression was also analysed in high Pi medium upon UV-radiation and 
cisplatin treatment.
For Western blot analysis of mutant p53 expression after UVC and cisplatin
treatment, the cells were grown in high Pi medium to the saturation and 10 ml of
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those saturated cells were exposed to 100 j/m^ UVC and 5 mM cisplatin. Cells were 
incubated at 30°C for 24 hr. After incubation the cells were lysed with Laemni lysis 
loading buffer. The proteins were fractionated by electrophoresis in a 10 % SDS 
polyacryamide gel and electroblotted to PVDF paper. p53 proteins probed with anti- 
p53 antibody HR231 and binding was visualised using colorimetric detection assay 
(Figl8).
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Fig.l8. Western blot analysis o f the mutant p53 e.xpression in yeast cells grown in higli Pi medium 
and e.xposed to UV-radiation or cisplatin treatment
In accordance with the previous Western blot analysis o f mutant p53 protein 
extracted from cells grown in low Pi medium, no difference for mutant p53 
expression was detected cells grown in high Pi medium
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5. DISCUSSION
Existence o f p53 homologue has not been demonstrated in yeast yet. The lack 
o f demonstrable p53 homologue in yeast however doesn’t discourage the further 
studies that use this organism to explore potential functions o f p53 because human 
p53 might function directly or indirectly by interacting with other macromolecules o f 
yeast that are functionally conserved between yeasts and mammals.
A growth inhibitoiy effect o f p53 on S.cerevisiae was clearly demonstrated 
with wild type p53 (Nigro et a l, 1992). This growth inhibition effect o f wild type 
p53 was also demonstrated in fission yeast S.pombe. The results clearly show 
analogy with the p53 colony growth inhibition effect in human tumuor cells that 
were transfected with wild type p53 genes (Baker et al., 1990; Diller et al., 1990).
This is the first known study to evaluate the effects o f p53 protein on yeast 
cell survival and response to DNA damaging agents. In this study yeast S.cerevisiae, 
AKY28 strain, was chosen as a model organism.
As a first step to study p53 effects in yeast, we established an experimental 
model. In this model, we used the expression vectors, pL3 and pAK31. pL3 was the 
original plasmid from which pAK31 was constructed and it was used as a control 
during the experiments. pAK31 was used as regulatable mutant p53-248W protein 
expressing vector. Regulation o f p53 expression was under the control o f  Pi 
regulated PH 05 promoter. Instead o f wild type p53, mutant p53-248W was used to 
establish this experimental system due to reported growth inhibitory effect o f wild 
type p53 on yeast cells (Bischoff et al., 1992; Nigro et al., 1992). In this system.
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initially, we verified the presence o f mutant p53 sequence (codon 248, R->W) in 
pAK31 and in yeast cells that were transfected with this plasmid. After the presence 
o f mutant p53 sequence in transfected yeast cells was confirmed, expression o f p53 
protein was analysed by Western blotting. The results indicated that p53 protein 
expression was not completely regulated by PH 05 promoter because p53 expression 
was detected in both high Pi and low Pi medium suggesting that PH 05 was not 
totally suppressed in high Pi medium. Although constitutive expression o f 
transfected wild type p53 may inhibit yeast cellular proliferation but in this case 
because o f  mutant p53-248 expression in yeast cells, regulatable expression o f  p53 
protein was not stringently required. After demonstrating mutant p53-248W 
expression in yeast cells, the growth rate o f p53 expressing and control cells was 
analysed. Serial yeast dilutions ranged from 10'^ dilution to 10'* dilution intervals 
were applied to agar plates and the growth rate of those cells was compared. No 
difference was detected between mutant p53-248W expressing and non-expressing 
(pL3 transformed) yeast cells.
The mutation in amino acid residue R248, one o f the most frequently altered 
residues in the protein, results in defective contact with the DNA and loss o f ability 
to act as a transcription factor (Cho et al., 1994). The mutant p53-248W exerts a 
trans-dominant loss o f function effect on wild type p53 protein in human cells 
(Hollenstain et al, 1991). A report that analysed dominant-selective mutants in 
S.cerevisiae demonstrated that the p53 mutations in codon 248 was one o f the most 
dominant-negative mutants that could interfere with one and two copies o f wild type 
p53 (Brahman et al., 1996). Demonstrated mutant p53-248W effects on S.cerevisiae 
growth showed analogy to report that demonstrate the effect using mutant p53-143A 
expression (Nigro et al., 1992). Ala 143'"‘ is a temperature sensitive mutant in
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mammalian cells that shows a wild type conformation at lower temperature (32°C) 
(Zhang et al., 1994). This mutant was previously shown to have strong dominant­
negative effects on p53 protein (Kern et al., 1992). According to report, the growth 
oiS.cerevisiae was affected by the A la-143 mutant much less dramatically than by 
wild type p53. Another mutant p53-273 H was shown to have recessive effect on p53 
protein (Chen et al., 1990) and behaved in an intermediate fashion (Nigro et al., 
1992). According to another report, mutant p53-273H and mutant p53-175H 
expression showed different effects on S.pombe yeast cell survival (Bischoff et al., 
1992). Although both mutants showed different growth rate effect compared to wild 
type p53, the mutant p53-175H showed the smallest effect and mutant p53-273H 
showed intermediate effect between wild type p53 and mutant p53-175H (Bischoff 
et al., 1992). It was previously shown that mutant p53-273H exerted recessive effect 
and mutant p53-175H exerted dominant effect on wild type p53 in both mammalian 
and yeast cells (Bischoff et al., 1992). These reports suggest that effect o f the mutant 
p53 protein on yeast cell growth rate vary according to type of the p53 mutation. In 
general, mutants that show a dominant effect on p53 protein, exert a smaller effect on 
yeast cell survival than mutants that show a recessive effect. In the case o f our study 
we demonstrated that mutant p53-248W which was previously shown to exert 
dominant loss o f fiinction effect on the wild type p53, doesn’t effect the growth rate 
o f yeast cells.
The effect o f  mutant p53 on yeast cell growth after DNA damage was also 
analysed. UVC and cisplatin were used as DNA damaging agents. Cell survival 
assay was performed using the same procedure that demonstrated p53 effect on yeast 
cell growth rate. No distinct mutant p53 effect on yeast cell survival was detected 
when mutant p53 expressing and non-expressing cells were compared. The effect o f
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p53 expression on cell survival upon exposure to UV-radiation was also studied in 
mammalian cells and it was reported that clonogenic survival o f the mouse cells 
expressing wild type p53 following UV-radiation enhanced upon DNA damage 
compared to non-induced mutant p53-143V expressing cells (Yuan et a l, 1995).
In parallel to the cell survival assay mutant p53-248W protein levels 
following cisplatin and UVC treatment were compared with untreated cells and no 
induction was detected. Similar analysis were also performed in mammalian cells 
and wild type p53 levels were shown to increase following y-irradiation, UV- 
radiation and treatment o f base adduct factors (Lane, 1993; Lu and Lane, 1993). 
Induction o f p53 in mouse fibroblast cell line was found to enhance the clonogenic 
survival o f the cells following UV-irradiation compared to p53-deficient parental 
mouse cells (Yuan et al., 1995).
In this study mutant p53-248W was used. 248R mutation is one o f the p53 
hot spot mutation in human cancers and its found in the DNA interacting face o f p53. 
Mutations in codon 248 result in defective contacts with DNA and loss o f ability as 
transcriptional factor (Cho et al., 1994; Scharer and Iggo et al., 1992). According to 
following reports in mammalian cells that study p53 response to DNA damage, 
mutant p53 248W exerted loss o f function phenotype compared to wild type p53 
function. The p53-248W mutant cells were more resistant than the wild type p53 
cells to UV cytotoxicity and exhibited less UV-induced apoptosis (Ford and 
Hanavalt, 1995). It was demonstrated that wild type p53 is required for heat shock 
and ultraviolet light enhanced repair o f a UV-damaged reporter gene in normal 
diploid fibroblasts however this inducible DNA repair response was absent in Li- 
Fraumeni syndrome (LFS) fibroblasts which are heterozygous for mutant p53-248W
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and immortalized LFS cell sublines, which express only mutant p53-248W (Mckay 
et al., 1997).
The obtained results were not unexpected because o f reported dominant­
negative effect o f mutant p53-248W in yeast and mammalian cells. It is possible that 
mutant p53-248W is defective for the functions o f p53 that provide its induction and 
following effect on cell survival upon DNA damage. But at this step we are not able 
to speculate about results without considering and comparing the wild type p53 
effects with demonstrated mutant p53-248W results obtained in this established 
experimental system.
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6.CONCLUSION
We established an experimental system to study p53 effects in yeast upon 
DNA damaging agents. Mutant p53-248W was used in studies. Although p53 effects 
on mammalian cell growth and p53 protein response was previously studied in 
mammalian cells, this is the first report about mutant p53 effects upon DNA damage 
in yeast. In this study it was initially shown that mutant p53-248W didn’t effect the 
growth rate o f yeast cells in normal conditions. This result was also confirmed by the 
previous reports that demonstrated nearly same effect (Nigro et al., 1992). We also 
demonstrated that mutant p53-248W expression did not effect yeast cell survival 
upon DNA damage and mutant p53-248W protein didn’t show any response like 
increase or decrease to those agents. The unresponsive effect o f mutant p53-248W on 
yeast cell survival upon DNA damage, is not an unexpected result because mutant 
p53-248W that is one o f the p53 mutations commonly found in human tumours, lose 
some o f the biological functions o f p53 in yeast that was reported previously in yeast 
S.cerevisiae (Schrarer and Iggo 1992).
This study based on an establishment o f experimental model to study p53 
effects in yeast. It shows that mutant p53-248W in yeast cells has no demonstrable 
effect on yeast cell growth after DNA damage.
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^PERSPECTIVES
We have established an experimental system to study the effects o f human 
wild type and mutant p53 in yeast cells. Mutant p53-248W expression vector, 
pAK31 was used to establish this system.
Next we will study the effects o f wild type p53 in this experimental system. 
Since growth inhibitory effects o f wild type p53 in yeast have already been shown, it 
will be more important to focus on the possible involvement o f wild type p53 in 
DNA damage response in yeast cells. As the expression system used here doesn’t 
allow full suppression, it may be necessary to construct another wild type p53 
expression vector under the control o f other inducible promoters. Because 
constitutive expression of transfected wild type p53 can inhibit cellular proliferation 
in yeast, we chose the mutant form of p53 protein to construct this experimental 
system. We can overcome this obstacle by using alternative regulatable p53 
expressing vectors.
After an appropriate wild type p53 expression vector is obtained, there are 
many different studies to performed in our experimental system that provides an easy 
system for studying the mechanism o f action o f human p53 in yeast upon DNA 
damage.
Induction o f p53 leads to either cell growth arrest or cell death. Apoptosis 
and growth arrest provide mechanisms by which p53 functions to control DNA 
damage, protecting cellular descendants from accumulating excessive mutation.
Many reports that provide information about factors involved in each o f these
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responses. However, there are still many questions to be answered (Shiomura et al., 
1996). Wild type p53-mediated growth responses like cell cycle arrest and apoptosis 
can be studied in yeast cells after DNA damage using this experimental system.
Wild type p53 is normally present in extremely small quantities. Induction o f 
p53 results in an increase in the levels o f p53. DNA damage induces p53 and causes 
its accumulation (Kastan et al., 1991). This response o f p53 can be studied in yeast 
cells exposed to DNA damaging agents.
Other strategies can be developed to understand action o f p53 in yeast cell 
upon DNA damage. One o f the strategies can be identification o f yeast and 
mammalian proteins that can modify p53-mediated growth control in yeast cells. 
Using in vitro systems, p53 protein interacting peptides can be isolated from a 
random peptides library. Also the in vivo yeast two-hybrid system provides high 
sensitive detection of this interaction, without any biochemical modifications. The 
yeast two hybrid system can be used to screen a library o f random peptides fused to a 
transcriptional activation domain in order to identify peptides capable o f binding to 
the DNA damage induced p53 protein.
Generation o f p53 response defective mutant yeast strains by mutagenesis 
might allow identification o f a yeast gene that complements p53 function induced 
upon DNA damage This yeast gene could be isolated from the mutant cells that were 
transformed with a library o f yeast genomic cDNA and identified by transposon 
insertion mutagenesis o f the cDNA expressing plasmid.
Also dominant-negative mutant p53 proteins that inactivate p53 function 
upon DNA damage can be determined using our established system by transfecting 
the mutant p53 protein in to the wild type p53 expressing yeast cells.
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Two different conformation o f p53 were detected based on their differential 
immunreactivity with specific antibodies: a “suppressor” conformation that inhibit 
cell division and a “promoter” conformation. The promoter conformation is 
generally characteristic o f mutant p53s found in human cancers (Gannon et al.,
1990). At present the mechanism responsible for this conformation is unknown. 
Using this established experimental system, those factors can be determined in 
response to DNA damaging agents that induce p53 activation.
There are also evidences for direct involvement of p53 in DNA repair but this 
function o f p53 has not been clarified yet. Yeast is the commonly preferred organism 
to study DNA repair system and homologous genes involved in DNA repair have 
been found in yeast and mammalian cells (Sancar, 1996). Recent studies have 
suggested p53 involvement in DNA repair (McKay et al., 1997; Smith et al., 1995), 
so similar assays might be applied in yeast using this established system.
Strategies can be developed more and more because p53 tumour suppressor 
has been the hot topic and studied by many researchers since 1979s. In this study we 
preferred to investigate p53 functions in yeast and as initial step we established an 
experimental system that is open to further investigations.
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